| Execution period | FY 2026-27 |
|---|
BSE filing, NSE: AJANTPHARM. Summary written from the filing by ALFA Finder's alert engine.
Ajanta Pharma Ltd: key numbers
- Share price
- ₹3,459.80
- Market cap
- ₹43,233 Cr
- Revenue (annual)
- ₹5,453 Cr
- Net profit (annual)
- ₹1,056 Cr
- P/E (TTM)
- 38.1×Sector 46.1×
- Promoter holding
- 63.47%-0.01% QoQ
- FII holding
- 7.62%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ajanta Pharma Ltd
All →Ajanta Pharma Share Pledge
Ajanta Pharma promoter Aayush Agrawal (trustee) created a pledge on 30,000 equity shares. The pledge was made as a top-up call due to share price reduction.
Ajanta Pharma Board Meeting Date
Ajanta Pharma has scheduled a Board meeting for 30 October 2026 to consider Q2/H1 2026 unaudited financial results. No material decision has been taken yet.
Ajanta Pharma Other Announcement
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Ajanta Pharma Share Pledge
Promoter Aayush Agrawal Trust created pledge on 4,60,000 Ajanta Pharma shares. The pledge secures an NCD issue in favor of CTL Trusteeship Ltd.
Ajanta Pharma Share Pledge
CTL Trusteeship Limited reported a pledge creation on 26,21,067 shares (2.10%) of Ajanta Pharma Limited to secure debentures worth Rs. 3,873 Crore. The shares act as collateral for NCDs issued by Lenexis Foodworks and Inspira Realty.
- Value
- ₹3,873 Cr
Ajanta Pharma Share Pledge
Ajanta Pharma promoter Aayush Agrawal Trust released a pledge on 98,185 equity shares. The release followed loan repayment to Aditya Birla Capital Ltd.
Other board meeting outcome announcements
All →R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.
M K Exim (India) Board Meeting Outcome
M.K. Exim (India) approved shifting its registered office within Jaipur to Plot J-1247, Sitapura. The board meeting was held on October 28, 2026.
United Spirits Board Meeting Outcome
United Spirits' board approved amendments to its insider trading code on 28 October 2026, effective 29 October 2026. The revised code is available on the company website.
SBI Funds Management Board Meeting Outcome
SBI Funds Management extended internal auditor Chhajed & Doshi's term to March 31, 2030. This routine decision was taken at the October 28, 2026 board meeting.
- Execution
- April 1, 2028 to March 31, 2030
Paras Healthcare Board Meeting Outcome
Paras Healthcare filed its board-approved UPSI fair disclosure code under Regulation 8(2). This routine governance policy update reports no business event.
Gateway Distriparks Board Meeting Outcome
Gateway Distriparks' board approved a revised Code of Practices for Fair Disclosure of UPSI under PIT Regulation 8(2). This is a routine governance policy update with no business event.